Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Cerebral palsy and spasticity

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Acute deterioration in cerebral palsy

New reduced consciousness, status epilepticus, aspiration, respiratory failure, shunt symptoms, severe dystonic crisis, painful hip displacement or unexplained loss of function requires urgent assessment rather than attribution to baseline disability.

Action: Use ABCDE, obtain the child's communication and emergency plan, treat pain and seizures, seek caregiver knowledge of baseline function and involve paediatrics with the relevant respiratory, neurological or orthopaedic team.

Synopsis

Recognise cerebral palsy early, define motor type and functional effect, investigate atypical progression and build a child-centred multidisciplinary plan for tone, pain, feeding, communication, hips and participation.

  • Cerebral palsy describes permanent disorders of movement and posture caused by a non-progressive disturbance in the developing brain; the child's manifestations and musculoskeletal consequences can change over time.
  • Classify the predominant motor pattern as spastic, dyskinetic, ataxic or mixed, then describe distribution, Gross Motor Function Classification System level and practical participation.
  • Early warning signs include abnormal fidgety movements, persistent fisting, early asymmetry, delayed milestones, abnormal tone and hand preference before one year.
  • MRI helps define timing and pattern when the cause is uncertain, but normal imaging does not exclude cerebral palsy; regression or progression demands reconsideration and often genetic or metabolic assessment.
  • Management begins with family goals, physiotherapy, occupational therapy, communication access, pain identification, nutrition, hearing, vision and education rather than reducing tone as an isolated target.
  • Before increasing tone treatment, look for pain, constipation, urinary retention, reflux, skin injury, poor seating and intercurrent infection that may be driving spasm or dystonia.
  • NICE uses oral diazepam when a rapid effect is needed and oral baclofen when a sustained effect is desired for generalised spasticity causing pain, spasm or disability.
  • Botulinum toxin type A is considered for focal spasticity impairing function, care, comfort or orthosis tolerance; combine it with goal-directed therapy and review effect.
  • Hip surveillance is systematic and based on clinical and radiographic risk, not merely reported pain; reduced abduction and asymmetry should accelerate orthopaedic review.
  • Assess swallowing and nutrition actively, offer augmentative communication early and plan transition before adolescence rather than waiting for paediatric services to end.

Key red flags

Loss of acquired skills, steadily progressive weakness, new sensory loss or increasing ataxia is inconsistent with the non-progressive brain disturbance defining cerebral palsy and requires diagnostic review.

Persistent feeding cough, recurrent chest infection, wet voice, prolonged meals or faltering growth suggests dysphagia and aspiration risk.

Pain, reduced hip abduction, asymmetric posture, difficulty with hygiene or declining transfers can indicate hip migration or dislocation before a child can localise pain.

Rapid worsening of generalised dystonia with fever, dehydration, pain or medicine withdrawal may evolve into life-threatening status dystonicus.

Early hand preference before 12 months, fisting, asymmetric movement, persistent primitive reflexes or delayed sitting and walking should trigger developmental assessment.

Constipation, urinary retention, reflux, dental pain, fracture and poor sleep commonly worsen tone; exclude these triggers before escalating antispastic medicines.

Investigation priorities

01
First-line multidisciplinary developmental assessmentFirst stepFirst line

Define motor type, distribution, functional level, associated impairment and family priorities.

Management branches

IdentifyRecognise early motor abnormality

An infant or child shows asymmetry, abnormal tone or delayed motor development.

  1. Refer for developmental and neurological assessment without waiting for a definitive label.
  2. Arrange early therapy, hearing, vision and communication support while investigations proceed.
  3. Use MRI and phenotype-led genetics when history and examination leave cause uncertain.

Key medicines

Oral baclofenFor children aged 1–17 years, specialist initiation commonly starts around 0.3 mg/kg/day in 2–4 divided doses, increasing at about weekly intervals toward 0.75–2 mg/kg/day; usual maxima are 40 mg/day below 8 years and 60 mg/day from 8 years.Titrate slowly because sedation, hypotonia and weakness can remove useful function; renal impairment increases toxicity and abrupt withdrawal can cause rebound spasticity, hallucinations, seizures and hyperthermia.
Botulinum toxin type ADose is calculated by product, body weight, muscle size and treatment goal within the paediatric spasticity service; units are not interchangeable between brands and the total session limit must follow that product's monograph.Use ultrasound or stimulation guidance where appropriate and plan post-injection therapy; warn about pain, temporary weakness and rare distant dysphagia or respiratory effects.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG62 Cerebral PalsyRecognition, causes, associated conditions, feeding, pain and multidisciplinary care under 25.
  • NICE CG145 Spasticity Under NineteenGoal-based physical, oral, focal, intrathecal and surgical spasticity management.
  • NHS Cerebral Palsy OverviewMotor types, associated needs and treatment overview for families.
  • NICE NG127 Neurological RecognitionEarly motor delay, weakness and regression referral features.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom